Sildenafil and phosphodiesterase-5 inhibitors for heart failure

Current Heart Failure Reports

Volumn 5, Issue 2, 2008, Pages 110-114

  Guazzi, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; MILRINONE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; RAMIPRIL; SILDENAFIL; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ADRENERGIC RECEPTOR BLOCKING; BLOOD VESSEL TONE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EXERCISE; GENE OVEREXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPOTENSION; LONG TERM CARE; LUNG CIRCULATION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG HEMODYNAMICS; MORBIDITY; MORTALITY; MUSCLE PERFUSION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; DRUG EFFECT; ENZYMOLOGY; EXERCISE TOLERANCE; FEMALE; HEART FUNCTION TEST; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HOSPITALIZATION; LUNG FUNCTION TEST; MALE; METABOLISM; PHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOTHELIUM, VASCULAR; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART FUNCTION TESTS; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROGNOSIS; PURINES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SULFONES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 58149131988     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-008-0018-9     Document Type: Review

References (36)

1. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1-e82.
2. Saraiva RM, Hare JM: Nitric oxide signaling in the cardiovascular system: Implications for heart failure. Curr Opin Cardiol 2006, 21:221-228.
3. Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664-666.
4. Kass DA, Champion HCE Beavo JA: Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007, 101:1084-1095.
5. Galiè N, Ghofrani HA, Torbicki A, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
6. Guazzi M, Samaja M: The role of PDE5-inhibitors in cardiopulmonary disorders: From basic evidence to clinical development. Curr Med Chem 2007, 14:2181-2191.
7. Takimoto E, Champion HC, Li M, et al.: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
8. Hassan MA, Ketat AF: Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 2005, 5:10.
9. Takimoto E, Champion HC, Belardi D, et al.: CGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005, 96:100-109.
10. Das A, Xi L, Kukreja RC: Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005, 280:12944-12955.
11. Fisher PW, Salloum F, Das A, et al.: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005, 111:1601-1610.
12. Pérez NG, Piaggio MR, Ennis IL, et al.: Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension 2007, 49:1095-1103
13. Nagendran J, Archer SL, Soliman D, et al.: Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116:238-248.
14. Borlaug BA, Melenovsky V, Marhin T, et al.: Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005, 112:2642-2649.
15. Al-Hesayen A, Floras JS, Parker JD: The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 2006, 8:864-868.
16. Guazzi M, Samaja M, Arena R, et al.: Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007, 50:2136-2144.
17. Lewis GD, Shah R, Shahzad K, et al.: Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007, 116:1555-1562.
18. Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure: The role of the endothelium in pathophysiology and management. Circulation 2000, 102:1718-1723.
19. Gehlbach BK, Geppert E: The pulmonary manifestations of left heart failure. Chest 2004, 125:669-682.
20. Guazzi M: Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest 2003, 124:1090-1102.
21. Guazzi M, Tumminello G, Di Marco F, et al.: The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004, 44:2339-2348.
22. Lewis GD, Lachmann J, Camuso J, et al.: Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115:59-66.
23. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF: Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005, 96:1436-1440.
24. Mahmud A, Hennessy M, Feely J: Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 2001, 15:707-713.
25. Oliver JJ, Melville VP, Webb DJ: Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006, 48:622-627.
26. Katz SD, Balidemaj K, Homma S, et al.: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000, 36:845-851.
27. Guazzi M, Casali M, Berti F, et al.: Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther 2008, 83:336-341.
28. Hryniewicz K, Dimayuga C, Hudaihed A, et al.: Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci 2005, 108:331-338.
29. Chen Y, Traverse JH, Hou M, et al.: Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2003, 284:H1513-H1520.
30. Forfia PR, Lee M, Tunin RS, et al.: Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007, 49:1079-1088.
31. Guazzi M, Reina G, Tumminello G, Guazzi MD: Exercise ventilation inefficiency and cardiovascular mortality in heart failure: The critical independent prognostic value of the arterial CO2 partial pressure. Eur Heart J 2005, 26:472-480.
32. Arena R, Myers J, Abella J, et al.: Development of a ventilatory classification system in patients with heart failure. Circulation 2007, 115:2410-2417.
33. Phillips BG, Kato M, Pesek CA, et al.: Sympathetic activation by sildenafil. Circulation 2000, 102:3068-3073.
34. Piccirillo G, Nocco M, Lionetti M, et al.: Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002, 143:703-710.
35. Bocchi EA, Guimaräes G, Mocelin A, et al.: Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: A double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002, 106:1097-1103.
36. Goldsmith SR: Type 5 phosphodiesterase inhibitioT in heart failure: the next step. J Am Coll Cardiol 2007, 50:2145-2147.